Short Interest in Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) Increases By 417.6%

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT) was the recipient of a significant growth in short interest during the month of July. As of July 31st, there was short interest totaling 296,924 shares, a growth of 417.6% from the July 15th total of 57,363 shares. Currently, 0.6% of the shares of the stock are sold short. Based on an average trading volume of 19,111,558 shares, the short-interest ratio is currently 0.0 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Zhengye Biotechnology from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, July 20th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Institutional Trading of Zhengye Biotechnology

Hedge funds have recently bought and sold shares of the business. Jane Street Group LLC acquired a new position in shares of Zhengye Biotechnology during the 2nd quarter worth approximately $1,158,000. WINTON GROUP Ltd grew its position in shares of Zhengye Biotechnology by 193.8% in the fourth quarter. WINTON GROUP Ltd now owns 63,297 shares of the company’s stock valued at $73,000 after purchasing an additional 41,750 shares in the last quarter. Invesco Ltd. acquired a new stake in shares of Zhengye Biotechnology in the second quarter valued at approximately $220,000. Geode Capital Management LLC acquired a new stake in shares of Zhengye Biotechnology in the second quarter valued at approximately $174,000. Finally, XTX Topco Ltd lifted its position in Zhengye Biotechnology by 71.4% during the fourth quarter. XTX Topco Ltd now owns 59,286 shares of the company’s stock worth $68,000 after buying an additional 24,697 shares in the last quarter.

Zhengye Biotechnology Price Performance

NASDAQ:ZYBT opened at $1.61 on Wednesday. The company’s 50-day moving average price is $1.20 and its 200-day moving average price is $1.01. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.14 and a quick ratio of 0.82. Zhengye Biotechnology has a twelve month low of $0.62 and a twelve month high of $13.08.

About Zhengye Biotechnology

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.